National Aeronautics and Space Administration National Aeronautics and Space Administration The U.S. Government's Official Web Portal National Aeronautics and Space Administration National Aeronautics and Space Administration
NASA Banner spacer Banner Spacer spacer spacer
Advanced Search
Go button
spacer About NASA About NASA Glenn Exploration Systems Mission Directorate
Space Flight Systems @ GRC
News & Events
Orion Project Office
Launch Systems Project Office
Constellation Office
Announcement Background spacer
Advanced Flight Projects Office
Role of Interleukin-2 Receptor in Signal Transduction and Gravisensing Threshold of T-Lymphocytes (Leukin)
 
Experiment/Payload Overview
   

Brief Summary

Leukin will study the signal transduction pathway of the activation of T-lymphocytes. This investigation will also determine if loss of Interleukin-2 receptor expression is the cause of inhibition. Microgravity will be used as an inhibitor of activation.


Principal Investigator

• Isabelle Walther, Ph.D., Swiss Federal Institute of Technology, Space Biology, Zurich Switzerland

Co-Investigator(s)/Collaborator(s)

Augusto Cogoli, Ph.D., Swiss Federal Institute of Technology, Space Biology, Zurich Switzerland
Millie Hughes-Fulford, Ph.D., University of California - San Francisco, San Francisco, CA
Proto Pippia, Ph.D., University of Sassari, Sassari, Italy

Payload Developer

Swiss Federal Institute of Technology, Space Biology, Zurich Switzerland

Sponsoring Agency

European Space Agency (ESA)

Expeditions Assigned

14

Previous ISS Missions

A previous Leukin investigation was flown on STS-107 (Columbia) in 2003. This investigation will fly again for ESA on Expedition 14.

 
Experiment/Payload Description
   

Research Summary

• Leukin will help investigators understand why single cells are sensitive to microgravity and to study the microgravity effect on the immune system cells.

• The results of Leukin will enable understanding of the cause of reduced immune function associated with spaceflight so crew members stationed on the Moon or on a Mars mission will remain healthy.

Description

The International Space Station provides a modern platform to study physiology and molecular changes in space. In addition, understanding these physiological changes provides knowledge that we can apply to common diseases found in the general population. The results also help us to understand microgravity-induced immunosuppression.

Early NASA studies demonstrated that the lymphocytes (white blood cells) had a decreased response to mitogen stimulation of growth. In the late 60?s returning Apollo astronauts were found to have reduced immune function after spaceflight, taking approximately 7 days to recover normal function. Astronauts exposed to microgravity did not respond to mitogen, a protein that encourages cell division, while cells belonging to non-flown astronaut backups had normal response.

The aim of Leukin is to study the signals which cause the activation of T-lymphocytes, white blood cells that play a central role in cell-mediated immunity. The focus is on the role of Interleukin-2 (IL-2), a hormone that stimulates the growth of T-lymphocytes and plays an instrumental role in the body?s response to pathogens (bacteria, viruses, fungi, etc.) and in the determination of its genetic expression (process by which a gene's DNA sequence is converted into the structures and functions of a cell).

 
Applications
   

Space Applications

Leukin may help scientists to better understand the depression of the immune system which occurs during spaceflight and, therefore, to devise more adequate preventive or corrective measures for crew members during long duration missions.

Earth Applications

Determining the factors which cause IL-2 suppression can help scientists on Earth better treat immunosuppressed patients.

 
 
Operations
   

Operational Requirements

Cells will be prepared at the launch site just prior to launch from fresh human blood. The purified T-lymphocytes will be loaded into experiment containers just prior to launch. Following arrival on ISS, fixative will be added to a specified group of the cells. Fixative will be added to another group of cells 30 minutes following arrival on ISS and to a third group 4 hours after arrival on ISS.

Operational Protocols

The T-lymphocytes will be purified and sealed in experiment containers shortly before launch. Once on orbit an astronaut will inject an activator. After intervals of 0 minutes, 30 minutes and 4 hours the cultures will be fixed, by injection of a preservation solution, frozen and returned to the investigators for analysis.

     
 
Related Web Sites
   


The information provided is courtesy of the ESA Astrolab Mission web page.
Space Biology Group
The Lab of Cell Growth - University of California Medical School, San Fancisco, CA

Images
FIT_1
Cell culture cassette system showing multi-injector unit used for spaceflight experiment. Image courtesy of NASA.

+ View Larger Image

 

ISS Research Program
Ames Research Center
Bion M-1
EMCS-TROPI
FIT
Foton-M3
MSat-FF
Ground Animal Research and BSP
Leukin
Microbe
MicroSat-1
PKINASE
SPEGIS
Glenn Research Center
Johnson Space Center
Kennedy Space Center
Marshall Space Flight Center
Human Research Program
Science Project Office
Advanced Capabilities Project Office
Space Operations Project Office
National Center for Space Exploration Research
External Partners
Education/Outreach
Space Exploration Benefits
Program Support

 

Footer seperator
FirstGov Logo

+ Freedom of Information Act
+ Privacy Policy and Important Notices
+ President's Commission on Moon, Mars and Beyond (PDF)

NASA Logo

Webmaster:
Tim Reckart
NASA Official: Thomas St. Onge
Last Updated: August 14, 2008
Footer spacer
Footer spacer